Aurinia Pharmaceuticals Inc (AUPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aurinia Pharmaceuticals Inc (AUPH) has a cash flow conversion efficiency ratio of 0.085x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($52.57 Million) by net assets ($614.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Aurinia Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
Aurinia Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Aurinia Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aurinia Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aurinia Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore AUPH cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Topoint Technology Co Ltd
TW:8021
|
0.048x |
|
CETC Energy Joint Stock Co Ltd
SHG:600877
|
-0.019x |
|
Navinfo Co Ltd
SHE:002405
|
-0.018x |
|
PLGO
NYSE:PLGO
|
0.122x |
|
OCADO GROUP SP.ADR 1/2
F:0OC1
|
N/A |
|
Kalbe Farma Tbk PT
JK:KLBF
|
0.041x |
|
LegoChem Biosciences Inc
KQ:141080
|
-0.093x |
|
HENSOLDT AG UNSP. ADS
F:HAG0
|
0.021x |
Annual Cash Flow Conversion Efficiency for Aurinia Pharmaceuticals Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Aurinia Pharmaceuticals Inc from 1998 to 2025. View AUPH stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $581.33 Million | $135.66 Million | 0.233x | +98.45% |
| 2024-12-31 | $377.48 Million | $44.39 Million | 0.118x | +232.82% |
| 2023-12-31 | $377.95 Million | $-33.46 Million | -0.089x | +54.87% |
| 2022-12-31 | $405.44 Million | $-79.53 Million | -0.196x | +40.40% |
| 2021-12-31 | $479.09 Million | $-157.69 Million | -0.329x | -92.12% |
| 2020-12-31 | $407.75 Million | $-69.86 Million | -0.171x | +19.54% |
| 2019-12-31 | $298.60 Million | $-63.59 Million | -0.213x | +53.55% |
| 2018-12-31 | $112.58 Million | $-51.61 Million | -0.458x | -84.57% |
| 2017-12-31 | $165.74 Million | $-41.17 Million | -0.248x | +52.28% |
| 2016-12-31 | $35.95 Million | $-18.71 Million | -0.521x | +41.51% |
| 2015-12-31 | $19.96 Million | $-17.77 Million | -0.890x | -137.47% |
| 2014-12-31 | $45.11 Million | $-16.90 Million | -0.375x | -10.20% |
| 2013-12-31 | $13.30 Million | $-4.52 Million | -0.340x | -111.01% |
| 2012-12-31 | $-2.12 Million | $-6.55 Million | 3.090x | +1561.34% |
| 2011-12-31 | $6.41 Million | $-1.36 Million | -0.211x | +69.06% |
| 2010-12-31 | $6.35 Million | $-4.34 Million | -0.683x | +68.57% |
| 2009-12-31 | $4.81 Million | $-10.46 Million | -2.175x | +1.59% |
| 2008-12-31 | $7.87 Million | $-17.39 Million | -2.210x | -120.61% |
| 2007-12-31 | $28.41 Million | $-28.46 Million | -1.002x | +3.95% |
| 2006-12-31 | $20.17 Million | $-21.03 Million | -1.043x | -108.06% |
| 2005-12-31 | $42.36 Million | $-21.23 Million | -0.501x | -29.84% |
| 2004-12-31 | $52.20 Million | $-20.15 Million | -0.386x | -415.36% |
| 2003-12-31 | $68.54 Million | $-5.13 Million | -0.075x | -319.16% |
| 2002-12-31 | $47.56 Million | $-849.90K | -0.018x | +91.30% |
| 2001-12-31 | $35.28 Million | $-7.25 Million | -0.205x | +54.55% |
| 2000-12-31 | $12.76 Million | $-5.77 Million | -0.452x | -6.20% |
| 1999-12-31 | $3.19 Million | $-1.36 Million | -0.426x | -120.49% |
| 1998-12-31 | $-846.35K | $-1.76 Million | 2.077x | -- |
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and … Read more